Top-News

Astellas Pharma Aktie News

Aktie
WKN:  A0YGQP ISIN:  US04623U1025 US-Symbol:  ALPMY Branche:  Pharmazeutika Land:  Japan
12,88 $
+0,16 $
+1,26%
11,062 € 05.12.25
Depot/Watchlist
Marktkapitalisierung *
18,85 Mrd. €
Streubesitz
99,98%
KGV
51,06
Faktor
1
Originalaktie
JP3942400007

Astellas Pharma News

01.10.25 - PR Newswire
Astellas To Present Pioneering Advances Across Its Portfolio and Pipeline at ESMO 2025
Astellas To Present Pioneering Advances Across Its Portfolio and Pipeline at ESMO 2025 PR Newswire
29.09.25 - PR Newswire
Astellas Announces Top Management Personnel Change
Astellas Announces Top Management Personnel Change PR Newswire
17.07.25 - PR Newswire
Astellas Announces a Partnership with the "Korea Institute of Startup and Entrepreneurship Development", an Umbrella Organization of the "Ministry of SMEs and Startups", a Korean Government Agency, for the Operation of the "Partnership with Global Companies Program"
Astellas Announces a Partnership with the "Korea Institute of Startup and Entrepreneurship Development", an Umbrella Organization of the "Ministry of SMEs and Startups", a Korean ...
13.06.25 - PR Newswire
Mitsubishi Research Institute and Astellas Announce Collaboration to Support Pharma Startups in Japan
Mitsubishi Research Institute and Astellas Announce Collaboration to Support Pharma Startups in Japan PR Newswire
29.05.25 - PR Newswire
Astellas Enters Exclusive License Agreement with Evopoint Biosciences for XNW27011, a Novel Clinical-stage Antibody-Drug Conjugate Targeting CLDN18.2
Astellas Enters Exclusive License Agreement with Evopoint Biosciences for XNW27011, a Novel Clinical-​stage Antibody-​Drug Conjugate Targeting CLDN18.2 PR Newswire
28.05.25 - PR Newswire
Astellas Announces Second Annual Patient Advocacy Organization (PAO) Action Week™ To Empower Patients and Caregivers
Astellas Announces Second Annual Patient Advocacy Organization (PAO) Action Week™ To Empower Patients and Caregivers PR Newswire
22.05.25 - PR Newswire
Astellas and Pfizer's XTANDI™ (enzalutamide) Shows Long-Term Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer
Astellas and Pfizer's XTANDI™ (enzalutamide) Shows Long-Term Overall Survival in Metastatic Hormone-​Sensitive Prostate Cancer PR Newswire
21.05.25 - PR Newswire
Astellas and MBC BioLabs Announce the 2025 Astellas Future Innovator Prize Awarded to DeepSeq.AI & Serna Bio
Astellas and MBC BioLabs Announce the 2025 Astellas Future Innovator Prize Awarded to DeepSeq.AI & Serna Bio PR Newswire
19.05.25 - PR Newswire
Astellas Presents New Data that Explores Potential of its Cancer Therapies at 2025 ASCO Annual Meeting
Astellas Presents New Data that Explores Potential of its Cancer Therapies at 2025 ASCO Annual Meeting PR Newswire
07.05.25 - PR Newswire
Notice of Nominees for Directors
Notice of Nominees for Directors PR Newswire
01.05.25 - PR Newswire
Astellas to Present New Data in Geographic Atrophy at Upcoming Ophthalmology Annual Congresses
Astellas to Present New Data in Geographic Atrophy at Upcoming Ophthalmology Annual Congresses PR Newswire
05.03.25 - PR Newswire
Astellas and YASKAWA Agree to Establish a Joint Venture Focused on Cell Therapy Manufacturing
Astellas and YASKAWA Agree to Establish a Joint Venture Focused on Cell Therapy Manufacturing PR Newswire
27.02.25 - PR Newswire
Astellas and MBC BioLabs Announce the Sixth Annual Astellas Future Innovator Prize
Astellas and MBC BioLabs Announce the Sixth Annual Astellas Future Innovator Prize PR Newswire
12.02.25 - PR Newswire
U.S. FDA Approves Expanded Label for Astellas' IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy
U.S. FDA Approves Expanded Label for Astellas' IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy PR Newswire
05.02.25 - PR Newswire
Astellas Submits New Drug Application for Conditional Approval of Avacincaptad Pegol for Geographic Atrophy in Japan
Astellas Submits New Drug Application for Conditional Approval of Avacincaptad Pegol for Geographic Atrophy in Japan PR Newswire
04.02.25 - PR Newswire
Astellas Makes Announcement about Management Structure
Astellas Makes Announcement about Management Structure PR Newswire
08.01.25 - PR Newswire
U.S. FDA Confirms Class 1 Resubmission of the Supplemental New Drug Application for IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy
U.S. FDA Confirms Class 1 Resubmission of the Supplemental New Drug Application for IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy PR Newswire
08.01.25 - PR Newswire
China's National Medical Products Administration (NMPA) Approves PADCEV™ in combination with KEYTRUDA® (pembrolizumab) for the Treatment of Advanced Bladder Cancer
China's National Medical Products Administration (NMPA) Approves PADCEV™ in combination with KEYTRUDA® (pembrolizumab) for the Treatment of Advanced Bladder Cancer PR ...
05.01.25 - PR Newswire
China's National Medical Products Administration (NMPA) Approves VYLOY™ (zolbetuximab) for First-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
China's National Medical Products Administration (NMPA) Approves VYLOY™ (zolbetuximab) for First-​Line Treatment of Advanced Gastric or Gastroesophageal Junction ...
19.12.24 - PR Newswire
Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases
Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases PR Newswire

Newssuche

Videos

newspaper
05.12.25 +1,73%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »